Highly cited articles and current hotspots
Studies with high co-citation counts often represent fundamental and fundamental research in the field and are generally published earlier. Except for the EPOS, we summarized the nine most co-cited articles, which can be divided into three categories: immune features and endotypes, clinical applications, and epidemiological analyses. Of these nine articles, 6 explored the inflammatory patterns in CRS in different countries or different endotypes, and they collectively focused on the cell expression profile and immune marker profile of CRS patients, such as T(H)1/ T(H)2 skewed inflammation [21-23,44-46]. In addition, two publications focused on clinical applications, respectively evaluating the effectiveness of SNOT-22 (a derivative of SNOT-20), a quality-of-life questionnaire for patients with CRS[47], and the clinical efficacy of Omalizumab[48]. Moreover, the last publication was the European international multicentre prevalence study of CRS[49]. It should be noted, however, that the value of an article is not reliably measured by co-citation alone, as the newly published articles will rank lower when analyzed in terms of citations independently. In contrast, many incoming articles have significantly impacted frontier research.
By analyzing the timing and frequency of keyword appearances, we could obtain the current frontier research about CRS and NPs. Subsequently, we grouped the current frontier research hotspots into three sections: monoclonal antibodies and biologics, Covid-19, Inflammatory response, and endotypes.